search

Active clinical trials for "Urinary Bladder Neoplasms"

Results 1221-1230 of 1252

Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and...

Bladder Cancer

Metabolomics is a complementary approach for identifying perturbed metabolic pathways. The goal of this study is to establish and validate an early diagnostic model for bladder cancer by metabolomics.

Unknown status12 enrollment criteria

Effect and Prognosis of Immunohistochemical Biomarkers Changes in Patients With Bladder Cancer After...

Bladder Cancer

Clinical trial to investigate the relationship between the expression of immunohistochemical biomarkers GATA-3, CK20, P53 and Ki67 in bladder cancer and pathological complete response after neoadjuvant chemotherapy.

Unknown status6 enrollment criteria

Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using...

Urinary Tract InfectionsBladder Cancer

Vikor Scientific Urine-IDTM is a molecular analysis technology which provides pathogen detection, quantification, and resistance gene identification. Urine-IDTM delivers its results through the technology platform Antibiotic Stewardship program (ABXAssist™), which provides results incorporating regional sensitivity and susceptibility patterns, medication costs, antibiotic spectrum of activity, and FDA guidance. This product aims to deliver prompt, patient-centered and value-based guidance to clinicians for antibiotic selection within 24 hours of delivery to testing facility. Proposed advantages of Vikor Scientific Urine-IDTM include: Expeditious result (within 24 hours post-lab arrival) Simultaneous detection of polymicrobial and monomicrobial infections Identification of 49 most common antibiotic resistance genes Provision of up-to-date regional sensitivity and susceptibility patterns Provision of cost-sensitive treatment options and FDA guidance Easy accessibility (mobile, web-portal and electronic health records Integration) This utility of this technology has yet to be investigated in a clinical study and could prove to be a viable alternative or adjunctive diagnostic tool to standard laboratory culture. Standard laboratory culture can take up to 7 days to return pathogen identification and antibiotic susceptibility, potentially delaying appropriate care and prolonging exposure to inappropriate empiric antibiotics. Our study aims to analyze the ability Vikor Scientific Urine-IDTM to improve time to identification of correct pathogen and accuracy of pathogen identification when compared to standard laboratory culture.

Unknown status11 enrollment criteria

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

Urinary Bladder Neoplasm

This study investigates if reduced muscle mass and muscle function predispose to poor completion of oncological treatment in patients with bladder cancer (including cancer of the renal pelvis, ureter and urethra) and if muscle mass and muscle function change during oncological treatment in these patients. It also evaluates biomarkers for sarcopenia.

Unknown status6 enrollment criteria

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

Radiation TherapyCancer17 more

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.

Unknown status7 enrollment criteria

Multi Institutional Study in Patient Presenting With Hematuria

Bladder CancerHematuria

The primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria.

Unknown status5 enrollment criteria

Autophagy Bladder Cancer

Bladder Cancer

• Bladder cancer is the most common malignancy of the urinary tract. It represents the 7th most commonly diagnosed cancer in male population worldwide and drops to the 11th when both genders are considered . According to the American cancer society's estimates of bladder cancer in 2017, the number of the new cases of bladder cancer is 79,030, and the mortality figures reached 16,870 .

Unknown status2 enrollment criteria

Compare the Quality of Life Between Patients With Conduit Diversions or Orthotopic Neobladders

Bladder Cancer

The aim of this study is to compare the health-related quality of life (HRQoL) between patients underwent conduit diversion and orthotopic neobladder after radical cystectomy. The investigators plan to use validated HRQoL questionnaires to learn about how the different urinary diversion operations affect the HRQoL of people living with bladder cancer. The findings from this study may help doctors and patients choosing the proper operation type.

Unknown status6 enrollment criteria

Molecular Markers of Chemosensitivity for Bladder Cancer

Bladder CancerEffects of Chemotherapy

The purpose of this study is to try to figure out some bio-markers of chemosensitivity for adjuvant chemotherapy for bladder cancer.

Unknown status12 enrollment criteria

Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology...

Bladder Cancer Transitional Cell Carcinoma

This study includes two semi-consecutive parts: Part I Open label, controlled, Calibration part aimed to calibrate the CellDetect® device for identifying bladder cancer cells in urine samples. Part II Prospective, controlled, blinded part to determine the performance of the CellDetect® device in monitoring bladder cancer recurrence in patients with a history of TCC, using urine cytology samples The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.

Unknown status30 enrollment criteria
1...122123124...126

Need Help? Contact our team!


We'll reach out to this number within 24 hrs